期刊
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
卷 113, 期 -, 页码 279-281出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2021.10.022
关键词
Pseudomonas aeruginosa; ceftazidime/avibactam; ceftolozane/tazobactam; imipenem/relebactam; meropenem/vaborbactam
资金
- Pfizer Inc.
This study evaluated the in vitro activity of four new generation beta-lactam/beta-lactamase inhibitor combinations against P. aeruginosa isolates from patients with skin and soft tissue infections worldwide. The results demonstrated potent activity and broad coverage of these recently approved drugs against contemporary P. aeruginosa isolates.
Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of beta-lactam/beta-lactamase inhibitor combinations (BL/BLI). Objectives: To evaluate the in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from patients hospitalized with skin and soft tissue infections (SSTIs) in several countries around the world. Methods: A total of 360 P. aeruginosa isolates were consecutively collected from 47 medical centers located in Western Europe, Eastern Europe, the Asia-Pacific region, and Latin America. Susceptibility testing was performed by broth microdilution method at a monitoring laboratory. EUCAST breakpoints were applied. Results: Ceftazidime/avibactam (98.3% susceptible), ceftolozane/tazobactam (98.6% susceptible), and imipenem/relebactam (98.3% susceptible) were the most active compounds after colistin (100.0% susceptible) and retained activity against isolates nonsusceptible to piperacillin/tazobactam, meropenem, imipenem, and/or ceftazidime. Meropenem-vaborbactam was active against 94.2% of isolates. Ceftazidime/avibactam was the most active BL/BLI against meropenem-nonsusceptible (92.6% susceptible) and imipenem-resistant (93.8% susceptible) isolates, whereas ceftolozane/tazobactam was the most active BL/BLI against piperacillin/tazobactam-resistant (91.1% susceptible) and ceftazidime-resistant (91.7% susceptible) isolates. Conclusions: The recently approved BL/BLIs demonstrated potent activity and broad coverage against contemporary P. aeruginosa isolates from patients with SSTIs. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据